Stocks › UTHR
UNITED THERAPEUTICS Corp
UTHR·Nasdaq·
United States·USD
$554.73
-4.37 (-0.78%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
UTHR
UNITED THERAPEUTICS Corp · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
UTHRS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of UTHR by members of U.S. Congress · 52 on record · 3 in the last 12 months
Whale Activity
Position changes in UTHR reported for 2026-09-30 by 962 institutional filers
- Increased281
- New79
- Held129
- Decreased326
- Closed113
- No prior filing34
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 5.6M | $3.02B | increased |
| Avoro Capital Advisors LLC | 2.8M | $1.49B | decreased |
| STATE STREET CORP | 2.0M | $1.06B | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.9M | $1.05B | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.9M | $1.04B | decreased |
| WELLINGTON MANAGEMENT GROUP LLP | 1.9M | $1.03B | increased |
| RENAISSANCE TECHNOLOGIES LLC | 1.7M | $908.2M | decreased |
| Amundi | 988.8K | $535.8M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 975.0K | $527.2M | decreased |
| CITADEL ADVISORS LLC | 928.5K | $503.1M | increased |
| Invesco Ltd. | 806.3K | $436.9M | increased |
| Janus Henderson Group Ltd. | 773.2K | $418.9M | — |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by UTHR insiders, by quarter · Form 4
Recent Insider Transactions
10,375 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −76 | $563.22 | $43K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −756 | $570.73 | $431K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −700 | $569.68 | $399K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −69 | $564.44 | $39K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −655 | $565.63 | $370K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −601 | $572.70 | $344K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −561 | $573.79 | $322K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −523 | $557.46 | $292K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −464 | $571.79 | $265K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −440 | $554.73 | $244K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −400 | $559.50 | $224K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −378 | $558.49 | $211K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −300 | $568.62 | $171K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −300 | $561.78 | $169K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −200 | $566.91 | $113K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −197 | $560.63 | $110K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −192 | $574.75 | $110K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −134 | $575.93 | $77K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −1,240 | $556.07 | $690K | Nov 19, 2026 | Form 4 ↗ |
| MAHON PAUL AEVP & GENERAL COUNSEL | Sale | −114 | $577.19 | $66K | Nov 19, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding UTHR · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF iShares Trust | 1.5M | $787.1M | 0.63% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.3M | $730.2M | 0.03% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 973.5K | $527.5M | 0.28% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 719.4K | $372.4M | 0.98% | Jul 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 486.6K | $263.6M | 0.27% | Jun 30, 2026 |
| State Street SPDR S&P MidCap 400SM ETF Trust SPDR S&P MIDCAP 400 ETF TRUST | 326.6K | $176.9M | 0.63% | Jun 30, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 308.3K | $167.1M | 0.25% | Jun 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 290.8K | $157.6M | 1.73% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 280.8K | $152.1M | 0.32% | Jun 30, 2026 |
| Invesco S&P MidCap Quality ETF Invesco Exchange-Traded Fund Trust | 266.2K | $137.8M | 2.53% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list UTHR's shares (CUSIP 91307C102), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Martine A. RothblattSCHEDULE 13G/A · passive (13G) · 1.7M shares4.0%
Nov 4, 2026 · ↗ - ROTHBLATT MARTINE ASCHEDULE 13G/A · passive (13G) · 2.3M shares5.3%
Aug 14, 2026 · ↗ - Wellington Investment Advisors Holdings LLPSCHEDULE 13G/A · passive (13G) · 1.4M shares3.2%
Aug 13, 2026 · ↗ - Wellington Group Holdings LLPSCHEDULE 13G/A · passive (13G) · 1.4M shares3.2%
Aug 13, 2026 · ↗ - Wellington Management Group LLPSCHEDULE 13G/A · passive (13G) · 1.4M shares3.2%
Aug 13, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming united therapeutics as client
- TIBER CREEK GROUPUNITED THERAPEUTICS CORPORATION · 2026 Q3 · HCR$80K
Filing ↗ - TIBER CREEK GROUPUNITED THERAPEUTICS CORPORATION · 2026 Q2 · HCR$80K
Filing ↗ - TIBER CREEK GROUPUNITED THERAPEUTICS CORPORATION · 2026 Q1 · HCR$80K
Filing ↗ - TIBER CREEK GROUPUNITED THERAPEUTICS CORPORATION · 2025 Q4 · POS$60K
Filing ↗ - TIBER CREEK GROUPUNITED THERAPEUTICS CORPORATION · 2025 Q3$20K
Filing ↗
Government Contracts
Federal awards to united therapeutics · USAspending
$200KAwarded · 11 contracts on record
- Department of Veterans AffairsTYVASO 0.6 MG REFILL KIT$30K
Aug 27, 2025 · ↗ - Department of Veterans AffairsTYVASO 0.6 MG REFILL KIT$0
Apr 8, 2026 · ↗ - Department of Veterans AffairsTYVASO 0.6 MG REFILL KIT$16K
Jul 21, 2026 · ↗ - Department of Veterans AffairsTYVASO 64 MCG KIT$17K
Jul 16, 2026 · ↗ - Department of Veterans AffairsTYVASO 64 MCG KIT$17K
Jul 9, 2026 · ↗ - Department of Veterans AffairsTYVASO 64 MCG KIT$17K
Jun 25, 2026 · ↗ - Department of Veterans AffairsTYVASO 64 MCG KIT$17K
Jun 11, 2026 · ↗ - Department of Veterans AffairsTYVASO 64 MCG$17K
Jun 5, 2026 · ↗
U.S. Patents
Recent USPTO applications naming UNITED THERAPEUTICS Corp
No USPTO patent applications found for UNITED THERAPEUTICS Corp.
Annual Financials
From UTHR's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.18B | $2.88B | $2.33B | $1.94B | $1.69B |
| Operating income | $1.49B | $1.38B | $1.18B | $979.7M | $555.9M |
| Net income | $1.33B | $1.20B | $984.8M | $727.3M | $475.8M |
| Diluted EPS | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 |
| Operating cash flow | $1.56B | $1.33B | $978.0M | $802.5M | $598.2M |
| Cash and equivalents | $1.56B | $1.70B | $1.21B | $961.2M | $894.8M |
| Total assets | $7.88B | $7.36B | $7.17B | $6.04B | $5.17B |
| Total liabilities | $783.8M | $920.0M | $1.18B | $1.25B | $1.21B |
| Shareholders' equity | $7.10B | $6.44B | $5.98B | $4.80B | $3.96B |
As UNITED THERAPEUTICS Corp tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 25, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 2-for-1Stock splitSep 23, 2009
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsOct 22, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsOct 14, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureSep 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 5, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureJul 23, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 29, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
EDGAR ↗
About UNITED THERAPEUTICS Corp
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSILVER SPRING, MD
IncorporatedDE
SEC CIK0001082554 ↗


